NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

新型冠狀病毒感染疾病(COVID-19):現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Coronavirus Disease 2019 (COVID-19) - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024225
出版日期 內容資訊 英文 315 Pages
商品交期: 3-5個工作天內
價格
新型冠狀病毒感染疾病(COVID-19):現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Coronavirus Disease 2019 (COVID-19) - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 315 Pages
簡介

本報告提供新型冠狀病毒感染疾病(COVID-19)市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病概要與流行病學研究

第4章 新型冠狀病毒感染疾病(COVID-19)的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 新型冠狀病毒感染疾病(COVID-19)的交易趨勢

第7章 新型冠狀病毒感染疾病(COVID-19)開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH1098

GervanoRA's pipeline analysis and opportunity assessment report "Coronavirus Disease 2019 (COVID-19) - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed COVID-19 pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in COVID-19 drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the COVID-19 area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in COVID-19 drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the COVID-19 historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current COVID-19 Market (2020) and the Forecasted COVID-19 Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of COVID-19 Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the COVID-19 Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of COVID-19 Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: COVID-19 CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF COVID-19 COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF COVID-19 PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: COVID-19 REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: COLLABORATION DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 03: FINANCING DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 04: LICENSING DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 05: MERGER AND ACQUISITION DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 06: PATENTS FILED BY INOVIO PHARMACEUTICALS
  • TABLE 07: PATENTS AND PATENT APPLICATIONS FILED BY ENTOS PHARMACEUTICALS
  • TABLE 08: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE III PIPELINE MOLECULES
  • TABLE 09: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE II/III AND PHASE IIB/III PIPELINE MOLECULES
  • TABLE 10: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE II PIPELINE MOLECULES
  • TABLE 11: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE I/II PIPELINE MOLECULES
  • TABLE 12: PHASE I PIPELINE MOLECULES FOR THE TREATMENT OF COVID-19
  • TABLE 13: PRECLINICAL MOLECULES FOR THE TREATMENT OF COVID-19
  • TABLE 14: EARLY RESEARCH AND DEVELOPMENT MOLECULES FOR THE TREATMENT OF COVID-19
  • TABLE 15: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 16: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
  • TABLE 17: LIST OF ANTIVIRAL THERAPEUTICS UNDERDEVELOPMENT
  • TABLE 18: LIST OF ANTIBODY-BASED THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 19: LIST OF SMALL MOLECULE THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 20: LIST OF VACCINES UNDER DEVELOPMENT
  • TABLE 21: LIST OF CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 22: LIST OF NON-CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 23: LIST OF COMPANIES DEVELOPING BIOLOGICAL ANIBODY BASED THERAPEUTICS
  • TABLE 24: LIST OF CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 25: LIST OF NON-CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 26: NON-CLINICAL PIPELINE DRUGS VS REPURPOSED DRUGS, NBES AND NCES
  • TABLE 27: COVID-19 PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 28: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF COVID-19 PIPELINE CANDIDATES

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE COVID-19 COMPETITIVE SPACE
  • FIGURE 02: GLOBAL INFECTED POPULATION FROM LAST FIVE MONTHS
  • FIGURE 03: RUSSIA, SPAIN, UK, ITALY, GERMANY AND FRANCE'S COVID-19 INFECTED POPULATION FROM LAST FIVE MONTHS
  • FIGURE 04: COVID-19 DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 05: INIDIVIDUAL DEAL STATISTICS FOR COLLABORATION DEALS
  • FIGURE 06: INIDIVIDUAL DEAL STATISTICS FOR FUNDING DEALS
  • FIGURE 07: INIDIVIDUAL DEAL STATISTICS FOR LICENSING DEALS
  • FIGURE 08: COVID-19 DEAL ANALYTICS BY DEAL FREQUENCY
  • FIGURE 09: DEALS ANALYTICS BY ACTIVE PLAYERS
  • FIGURE 10: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 11: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 12: COVID-19 DRUGS PIPELINE ANALYTICS BY ROA
  • FIGURE 13: COVID-19 DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
  • FIGURE 14: PARENTERAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 15: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 16: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE 17: LIST OF COMPANIES WITH RESPECT TO THE DRUG CLASSES
  • FIGURE 18: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 19: COVID-19 PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
  • FIGURE 20: COVID-19 PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • FIGURE 21: COVID-19 PIPELINE DRUGS ANALYTICS BY REPURPOSED DRUGS, NBES AND NCES
  • FIGURE 22: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON COVID-19